Relationship between LAPTM 4 B gene polymorphism and susceptibility of renal cell carcinoma and bladder cancer
Relationship between LAPTM 4 B gene polymorphism and susceptibility of renal cell carcinoma and bladder cancer
复制标题
DOI：
--
复制
发表时间：
2016
期刊：
影响因子：
--
通讯作者：
Dongmei Chen;Yanli Chang;Jian-jun Xu;Qingyun Zhang
中科院分区：
文献类型：
--
作者：
Dongmei Chen;Yanli Chang;Jian-jun Xu;Qingyun Zhang
溶酶体相关蛋白跨膜蛋白-4β(LAPTM4B)基因有两个等位基因，LAPTM4B*1和LAPTM4B*2。以往的研究表明，LAPTM4B*2与癌症风险有关。本研究旨在探讨LAPTM4B基因多态性与肾癌(RCC)和膀胱癌(BCA)易感性的关系。对180例肾癌、91例BCA和347例对照进行病例对照分析。采用聚合酶链式反应和电泳法分析LAPTM4B基因多态性。用卡方检验计算癌症患者和对照组之间的基因频率和其他参数分布。采用非条件Logistic回归模型计算优势比(OR)，可信区间(CI)为95%。结果显示，LAPTM4B*2等位基因频率在对照组(24.06%)显著低于肾癌(31.70%，P=0.008)和良性鳞癌(35.71%，P=0.009)。与携带LAPTM4B*1相比，携带LAPTM4B*2的肾癌和肾癌的风险分别增加1.467倍(95%CI 1.104~1.950)和1.634倍(95%CI 1.132~2.360)。携带LAPTM4B*1/2和*2/2的肾癌风险分别比携带LAPTM4B*1/1和LAPTM4B*1/2的患者高1.476(95%CI 1.008~2.161)和2.231(95%CI 1.089~4.569)。LAPTM4B*2/2是1.563倍(95%可信区间，0.932~2.622)和2.900倍(95%CI，1.233~6.821)。除吸烟状况外，LAPTM4B基因与肾癌和胆囊癌的临床参数无关联。结论：LAPTM4B*2是肾癌和BCA的危险因素。LAPTM4B可作为肾癌和BCA易感性的潜在生物标志物。
Lysosomal-associated protein transmembrane-4 beta (LAPTM4B) gene has two alleles, LAPTM4B*1 and LAPTM4B*2. Previous studies have demonstrated that LAPTM4B*2 contributed to the risk of cancers. This study aimed to investigate the correlation between LAPTM4B polymorphism and the susceptibility to renal cell carcinoma (RCC) and bladder cancer (BCA). A case-control analysis was performed in 180 RCC and 91 BCA cases and 347 controls. LAPTM4B polymorphism was analyzed by polymerase chain reaction and electrophoresis. Chi-square test was used to calculate genotype frequency and other parametric distributions between cancer cases and controls. Unconditional logistic regression analysis models were used to calculate odds ratio (OR) with 95% confidence interval (CI). Results showed that allelic frequency of LAPTM4B*2 in the controls (24.06%) was significantly lower than in RCC (31.70%, P = 0.008) and BCA (35.71%, P = 0.009) cases. The risks for RCC and BCA increased 1.467 (95% CI 1.104-1.950) and 1.634 (95% CI 1.132-2.360) times in individuals carrying LAPTM4B*2 compared with those carrying LAPTM4B*1. RCC cases with LAPTM4B*1/2 and *2/2 have 1.476 (95% CI 1.008-2.161) and 2.231 (95% CI 1.089-4.569) higher risks than those carrying LAPTM4B*1/1. BCA risk in cases carrying LAPTM4B*1/2 and LAPTM4B*2/2 was 1.563-fold (95% CI, 0.932-2.622) and 2.900-fold (95% CI, 1.233-6.821) that of cases with LAPTM4B*1/1. No association between LAPTM4B genotypes and clinical parameters of RCC and BCA was found, except for smoking status in BCA. Conclusions: These findings suggested that LAPTM4B*2 was a risk factor for both RCC and BCA. LAPTM4B is a potential biomarker for susceptibility of RCC and BCA.